Avadel vs. Jazz Pharmaceuticals: Sodium Oxybate Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. |
| Case Number | 1:25-cv-00196 (D. Del.) |
| Court | Delaware District Court |
| Duration | February 18, 2025 – February 27, 2025 9 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Jazz’s XYWAV |
Case Overview
The Parties
⚖️ Plaintiff
Commercial entity behind LUMRYZ™ (sodium oxybate), an FDA-approved, once-nightly extended-release treatment for cataplexy and excessive daytime sleepiness associated with narcolepsy.
🛡️ Defendant
Global biopharmaceutical company and the maker of XYWAV, a lower-sodium oxybate formulation also approved for narcolepsy indications.
Patents at Issue
This case involved two recently issued patents covering formulation and dosing technology central to Avadel’s LUMRYZ™:
- • US12226388B2 — Formulation and dosing technology for extended-release sodium oxybate
- • US12226389B2 — Further related to extended-release sodium oxybate formulations
Developing a similar pharmaceutical product?
Check if your sodium oxybate formulation might infringe these or related patents.
Litigation Timeline & Procedural History
Outcome
All claims were dismissed without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. The court issued no ruling on patent validity, claim construction, or infringement.
Procedural Details
The case was terminated at the first-instance trial level, well before any scheduling order, claim construction proceeding, or substantive motion practice could develop. The dismissal was filed under Rule 41(a)(1)(A)(i), which permits a plaintiff to voluntarily dismiss without a court order before the defendant has served an answer or motion for summary judgment — underscoring how early in the procedural lifecycle this action ended.
Developing a new drug formulation?
Learn from this case. Use AI to draft stronger claims for your pharmaceutical patents.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the sodium oxybate market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this rapid litigation.
- View all related patents in this therapeutic area
- See which companies are most active in CNS drug patents
- Understand procedural nuances of Rule 41(a)(1)(A)(i) dismissals
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or product.
- Input your drug description or formulation features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for your IP strategy
Dismissed Without Prejudice
Risk remains, re-filing possible.
New Patents Asserted
Signals active IP prosecution by Avadel.
Strategic Use of Dismissal
Suggests potential settlement or strategic pivot.
✅ Key Takeaways
For Patent Attorneys & Litigators
Rule 41(a)(1)(A)(i) dismissals preserve re-filing rights and can be used as strategic tools without prejudicing the merits.
Search related case law →Newly issued patents on commercial products signal ongoing prosecution and enforcement intent.
Explore precedents →For IP Professionals
Monitor continuation patent families around competing products — new grants create fresh infringement exposure windows.
Start FTO analysis for my product →A “closed” docket status does not equal resolved IP risk; track related patent families and PTAB proceedings.
Try AI patent drafting →For R&D Leaders
Extended-release formulation patents remain aggressively protected; conduct FTO analysis against the full patent family, not individual patents.
Start FTO analysis for my product →Nine-day litigation cycles can still signal significant competitive IP activity warranting internal review.
Learn more about patent landscape analysis →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.